Immatics (IMTX) Competitors $6.33 +0.43 (+7.29%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$6.33 0.00 (0.00%) As of 08/15/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMTX vs. MOR, NAMS, AMRX, RARE, KYMR, IMVT, HCM, XENE, ALVO, and CRNXShould you be buying Immatics stock or one of its competitors? The main competitors of Immatics include MorphoSys (MOR), NewAmsterdam Pharma (NAMS), AMNEAL PHARMACEUTICALS (AMRX), Ultragenyx Pharmaceutical (RARE), Kymera Therapeutics (KYMR), Immunovant (IMVT), HUTCHMED (HCM), Xenon Pharmaceuticals (XENE), Alvotech (ALVO), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. Immatics vs. Its Competitors MorphoSys NewAmsterdam Pharma AMNEAL PHARMACEUTICALS Ultragenyx Pharmaceutical Kymera Therapeutics Immunovant HUTCHMED Xenon Pharmaceuticals Alvotech Crinetics Pharmaceuticals MorphoSys (NASDAQ:MOR) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership. Which has more volatility & risk, MOR or IMTX? MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Immatics has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Is MOR or IMTX more profitable? Immatics has a net margin of -59.29% compared to MorphoSys' net margin of -226.79%. Immatics' return on equity of -15.60% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Immatics -59.29%-15.60%-12.31% Does the media favor MOR or IMTX? In the previous week, Immatics had 11 more articles in the media than MorphoSys. MarketBeat recorded 11 mentions for Immatics and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 1.08 beat Immatics' score of -0.08 indicating that MorphoSys is being referred to more favorably in the media. Company Overall Sentiment MorphoSys Positive Immatics Neutral Which has preferable valuation & earnings, MOR or IMTX? Immatics has lower revenue, but higher earnings than MorphoSys. Immatics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45Immatics$130.13M5.91$16.47M-$0.65-9.74 Do institutionals and insiders hold more shares of MOR or IMTX? 18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate MOR or IMTX? Immatics has a consensus target price of $14.67, suggesting a potential upside of 131.70%. Given Immatics' stronger consensus rating and higher possible upside, analysts plainly believe Immatics is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Immatics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryImmatics beats MorphoSys on 12 of the 17 factors compared between the two stocks. Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMTX vs. The Competition Export to ExcelMetricImmaticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$769.41M$3.14B$5.72B$9.79BDividend YieldN/A2.22%3.91%4.13%P/E Ratio-9.7421.0331.1425.06Price / Sales5.91285.40416.7890.80Price / Cash25.9142.6136.7858.67Price / Book1.468.659.086.18Net Income$16.47M-$54.65M$3.26B$265.11M7 Day Performance2.43%6.56%7.39%4.22%1 Month Performance1.93%4.82%4.22%0.77%1 Year Performance-45.00%15.81%30.30%24.69% Immatics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMTXImmatics2.0909 of 5 stars$6.33+7.3%$14.67+131.7%-45.0%$769.41M$130.13M-9.74260News CoverageEarnings ReportAnalyst RevisionMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsNAMSNewAmsterdam Pharma3.5385 of 5 stars$24.37-3.7%$41.20+69.1%+56.4%$2.84B$45.56M-15.044AMRXAMNEAL PHARMACEUTICALS3.0624 of 5 stars$8.84+3.5%$11.60+31.2%+17.5%$2.68B$2.79B884.888,100News CoverageInsider TradeRAREUltragenyx Pharmaceutical4.6666 of 5 stars$27.39-0.5%$81.50+197.6%-44.0%$2.65B$560.23M-4.951,294KYMRKymera Therapeutics2.7995 of 5 stars$37.68-7.2%$59.11+56.9%-2.7%$2.65B$47.07M-12.15170Trending NewsEarnings ReportAnalyst DowngradeAnalyst RevisionHigh Trading VolumeIMVTImmunovant2.8997 of 5 stars$14.76-4.5%$35.33+139.4%-49.4%$2.64BN/A-5.39120News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionHCMHUTCHMED2.6607 of 5 stars$15.48+3.2%$28.00+80.9%-10.9%$2.62B$630.20M0.001,811Analyst DowngradeXENEXenon Pharmaceuticals2.0263 of 5 stars$34.11+2.0%$54.33+59.3%+0.8%$2.57B$9.43M-10.56210Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionALVOAlvotech2.7826 of 5 stars$8.52+0.7%$14.00+64.3%-38.2%$2.55B$491.98M23.031,032Trending NewsEarnings ReportShort Interest ↓CRNXCrinetics Pharmaceuticals3.4688 of 5 stars$27.38+2.0%$68.86+151.5%-40.5%$2.53B$1.04M-6.66210 Related Companies and Tools Related Companies MorphoSys Competitors NewAmsterdam Pharma Competitors AMNEAL PHARMACEUTICALS Competitors Ultragenyx Pharmaceutical Competitors Kymera Therapeutics Competitors Immunovant Competitors HUTCHMED Competitors Xenon Pharmaceuticals Competitors Alvotech Competitors Crinetics Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMTX) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access